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Editorial: 
 
Ischaemia reperfusion injury at the time of lung transplantation may lead to primary graft dysfunction 
(PGD).1 Occurring within the first 72 hours following allograft reperfusion, PGD is characterised by 
hypoxaemia and alveolar infiltrates in the transplanted organ,  and occurs in up to 30% of patients.2 
The development of PGD carries significant early mortality of up to 50% in 30 days.3 Those who survive 
the early post-operative period have a higher propensity to develop bronchiolitis obliterans syndrome 
(BOS),4 and long term mortality is also higher at 1, 5 and 10 years.5 
 
Several risk factors have been identified for the development of PGD including a donor history of 
smoking, higher FiO2 at the time of reperfusion, elevated pulmonary arterial pressures, large volume 
blood transfusion and raised recipient body mass index.6 Increased length of ischaemic time has also 
been associated with the condition.6 This observation has led to the development of ex vivo lung 
perfusion (EVLP). Here lungs are ventilated and perfused with an acellular buffer. Use of this technique 
has allowed longer total ischaemic time prior to transplantation without an increase in incidence of 
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PGD.7 However incomplete understanding of the immune mechanisms leading to ischaemia 
reperfusion injury is a major limitation to preventing disease onset. There are no disease-specific 
therapeutics available for the condition, nor to prevent progression to PGD. Improved understanding 
of the immune responses underlying ischaemia reperfusion injury may allow development of new 
therapeutic strategies.  
 
Dysregulation of the innate immune response is central to ischaemia reperfusion pathobiology. 
Neutrophils are a recognised early protagonist of inflammation,8 with extravasation mediated by 
preceding monocyte recruitment.9,10 Monocytes are mononuclear phagocytes, and, in a most 
simplistic description belong to 2 principle subsets. Classical monocytes (Ly-6CHighCCR2+ in mice) are 
migratory leukocytes in response to injury or inflammation.11 They may phagocytose pathogens, 
present antigens via MHCII or secrete chemokines to recruit other cells to the site of inflammation. In 
lung, classical monocytes may traffic into the interstitium and differentiate to form alveolar 
macrophages or dendritic cells. Alveolar macrophages are a crucial mediator of the early inflammatory 
response and deletion of these cells is protective in experimental ischaemia reperfusion injury.12 Non-
classical, endothelial patrolling monocytes (Ly-6CLowCX3Cr1High in mice) have been shown to adhere to 
vascular endothelium, slowly crawling via integrin-cell adhesion molecule interactions.13 These 
monocytes are also capable of migration and further differentiation.  
 
It is recognised that circulating monocytes can be transferred from donor to recipient during 
transplantation.14,15 These cells remain present in lung explants following 10 litres perfusion, and 
donor monocytes remain detectable in the recipient’s circulation many months following 
transplantation.14 However the role of these ‘intravascular passenger’ monocytes in ischemia 
reperfusion injury has not been previously appreciated. In this issue of Thorax Tatham et al 
demonstrate a specific role of donor lung-marginated intravascular monocytes in ischaemia 
reperfusion injury during lung transplantation.16  
 
In a mouse model of ex vivo perfusion, a dual intravascular and intra-alveolar antibody delivery 
technique followed by tissue dissociation and flow cytometry allowed the authors to identify and 
enumerate intravascular monocytes and interstitial macrophages. Intriguingly despite intravascular 
perfusion for 15 minutes, approximately half of Ly-6CHigh and Ly-6CLow intravascular monocytes were 
retained within the lung. The activation status of these retained monocytes during ischaemia 
reperfusion was determined by modelling 2 hours of warm normoxic ischaemia followed by 2 hours 
of reperfusion incorporating three open-circuit washout periods with comparison to reperfusion only. 
L-selectin (CD62L) is expressed by Ly-6CHigh monocytes that have recently left bone marrow and is 
required for trafficking to lymph nodes and tissue during inflammation.17 On contact with vascular 
endothelium CD62L is downregulated and as part of monocyte maturation/differentiation markers 
including the co-stimulatory molecule CD86 are increased. Tatham and colleagues demonstrated that 
following ischaemia reperfusion there was activation of intravascular Ly-6CHigh monocytes with 
reduced L-selectin and increased CD86 expression.16  Ly-6CLow monocytes, which do not express high 
levels of L-selectin also demonstrated increased CD86 expression following ischaemia reperfusion. 
Together this demonstrated activation of the donor intravascular monocyte pool. 
 
Tatham and colleagues then selectively depleted intravascular monocytes using intravenous liposomal 
clodronate injection 24 hours prior to experimental lung perfusion in order to determine the effect of 
these vascular passenger cells on ischaemia reperfusion injury.16 This method significantly reduced Ly-
6CHigh and Ly-6CLow monocytes in the vascular compartment, whilst vascular neutrophils, interstitial 
macrophages and alveolar macrophage frequencies were unaltered. Wet:dry lung ratios and BAL 
protein concentrations, both biomarkers of pulmonary inflammation, were significantly reduced in 
liposomal clodronate-treated mice following ischaemic reperfusion. Consistent with this, MIP-2 
(CXCL2), a murine functional homologue of the powerful neutrophil chemo-attractant IL-8 (CXCL8),18 
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and shown to recruit neutrophils in experimental PGD,10 was significantly reduced post reperfusion in 
the monocyte-depleted group.16 MCP-1 (CCL1) is an important chemokine for monocyte adhesion to 
vascular endothelium during trafficking to inflammatory sites.19 Consistent with lack of consumption 
by monocytes,20 this chemokine was significantly increased in the liposomal clodronate group.16 The 
authors also demonstrated a reduction in the epithelial cell injury marker RAGE in the monocyte 
deplete mice, highlighting a potential early role for monocytes in ischaemia reperfusion, and hence 
PGD development. 
 
Finally, Tatham and colleagues analysed the presence of donor monocytes and granulocytes in lung 
tissue from a small cohort of 13 human lungs prior to implantation.16 Consistent with their murine 
observations, despite anterograde and retrograde perfusion of 5 litres of perfusate, high numbers of 
donor monocytes and neutrophils were still found in tissue. Electron microscopy confirmed the 
presence of monocytes and neutrophils in human lung capillaries, with possible cell to cell interactions 
between leukocytes and endothelial cells. Following transplantation total monocyte numbers and 
intensity of CD86 staining were shown as inversely correlated with PaO2:FiO2 ratios at 72 hours and 
48 hours respectively. Those who went on to develop Grade 2 or 3 PGD at 48 hours had higher 
expression of the monocyte activation markers CD86 and TREM-1. 
 
The experimental data presented by Tatham et al,16 suggests a previously unappreciated role of 
‘passenger’ intravascular donor monocytes in PGD following lung transplantation. Whilst limited 
human data is presented in this manuscript, high numbers of monocytes appear to be retained in 
human lung following standard perfusion protocols. Strengthening the findings of this paper is a 
recent confirmatory study of the importance of donor intravascular monocytes for neutrophil 
chemotaxis during PGD.10 The ability of these cells to withstand perfusion implicates high-affinity 
adhesive interactions between monocytes and endothelial cells. If mechanical removal of these cells 
prior to implantation is not clinically feasible, further elucidating the regulation of monocyte adhesion 
and trafficking, including the role of chemokine ligand/receptor pairs, and integrin/cell adhesion 
molecule interactions is of high importance in order to identify potential disease-selective therapeutic 
strategies. Future studies will also be required to examine whether ex vivo perfusion may provide a 
novel means of safely delivering therapy to the donor organ prior to transplantation, whether this 
approach may avoid systemic toxicity, and if donor intravascular monocyte-targeted therapy may 
reduce the incidence of PGD or modify the natural history of this devastating condition. 
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